Binimetinib vs Luvometinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MEK1/2 · full Non-Small Cell Lung Cancer pipeline
Binimetinib
Marketed by Pfizer and partners
NCT03915951 · Phase 2 · completed
This was a single-group, open-label study of 98 participants receiving encorafenib plus binimetinib, without randomization or a placebo or active-control arm. The primary imaging-based tumor-response endpoint was reported descriptively, so there was no controlled statistical comparison demonstrating that binimetinib improved outcomes.
Next expected readout: August 2027 · NCT05355701 (registry estimate)
No aligned efficacy figure on record for this race.
Luvometinib
Marketed by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2029 · NCT07562581 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Binimetinib | Luvometinib |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | 74.6%bNCT039159513 other results
| —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- Binimetinib
- —Not reported
- Luvometinib
- —Not reported
OS, median
- Binimetinib
- —Not reported
- Luvometinib
- —Not reported
ORR
- Binimetinib
- 74.6%bNCT03915951
3 other results
- 46.2% NCT03915951
- 62.7% NCT03915951
- 41% NCT03915951
- Luvometinib
- —Not reported
Duration of response, median
- Binimetinib
- —Not reported
- Luvometinib
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Luvometinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Binimetinib: 3 of 4 rows · Luvometinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Binimetinib |
|---|---|
| Dropout rate | n/a: no completion milestonePreviously Treated NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more resultn/a: no completion milestoneTreatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 |
| Discontinued due to AEs | 15.4%Previously Treated NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more result20.3%Treatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 |
| Serious AEs | 43.6%Previously Treated NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more result42.4%Treatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 |
| Most frequent reported AEs | diarrhoea 51.3% nausea 48.7% fatigue 41% NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more resultnausea 62.7% diarrhoea 49.2% fatigue 49.2% NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Binimetinib
show 3 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Binimetinib's landscape · Luvometinib's landscape